<div id="readability-page-1"><h3>Claim 30% Off TipRanks</h3><ul><li>Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions </li><li> Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks </li></ul>An announcement from Genprex ( (GNPX) ) is now available. On April 21, 2026, Genprex announced a new Sponsored Research Agreement with The University of Texas MD Anderson Cancer Center to study biomarkers that may predict patient response to its Reqorsa Gene Therapy in lung cancer. Preclinical work has highlighted TROP2 and PTEN as potential biomarkers, which could sharpen patient selection for the company’s Acclaim-1 and Acclaim-3 clinical trials and potentially improve clinical outcomes. The company reported that its Acclaim-1 Phase 1/2 trial in late-stage NSCLC combining Reqorsa with Tagrisso has advanced into Phase 2a after Phase 1 showed Reqorsa was generally well tolerated, with no dose-limiting toxicities and early signs of efficacy, including a durable partial response. Genprex also said its Acclaim-3 Phase 1/2 trial in extensive-stage SCLC combining Reqorsa with Tecentriq has moved into Phase 2 after a clean safety profile in Phase 1 and an unconfirmed partial remission lasting more than 18 months for one patient, underscoring the potential clinical promise of its gene therapy platform. Separately, Genprex released an updated investor presentation, available on its website, for use in meetings with investors, analysts and other stakeholders on or after April 21, 2026. The new data and research collaboration reinforce the company’s positioning as an emerging player in gene therapy-based oncology, with ongoing clinical validation efforts that could influence future treatment paradigms in lung cancer. More about Genprex Genprex, Inc. is a clinical-stage biopharmaceutical company focused on developing gene therapies for oncology, with a lead candidate, Reqorsa Gene Therapy (quaratusugene ozeplasmid), in development for non-small cell lung cancer and small cell lung cancer. The company collaborates with major cancer centers and large pharma partners to test Reqorsa in combination with approved therapies such as AstraZeneca’s Tagrisso and Genentech’s Tecentriq. Average Trading Volume: 796,370 Technical Sentiment Signal: Sell Current Market Cap: $11.58M Learn more about GNPX stock on TipRanks’ Stock Analysis page.</div>

GNPX

SBIO

ARKG

LABU

Genprex has announced a new Sponsored Research Agreement with The University of Texas MD Anderson Cancer Center to study biomarkers for its Reqorsa Gene Therapy in lung cancer. The collaboration aims to enhance patient selection for ongoing clinical trials, Acclaim-1 and Acclaim-3, which have shown promising results. The company is positioning itself as a key player in gene therapy for oncology, with ongoing efforts to validate its treatments. Genprex's market cap is currently $11.58M, and it has released an updated investor presentation for stakeholders.

Genprex Expands Lung Cancer Gene Therapy Research Collaboration